Bellerophon Therapeutics, Inc. (BLPH) belonging to the Medical sector has surged 2.07% and closed its last trading session at $1.48.
The company reported its EPS on 03/13/2017. Currently, the stock has a 1 Year Price Target of $4.75.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Bellerophon Therapeutics, Inc. on 03/13/2017 reported its EPS as $-0.36 with the analysts projecting the EPS of the stock as $-0.21. The company beat the analyst EPS Estimate with the difference of $-0.15. This shows a surprise factor of -71.4%.
Many analysts have provided their estimated foresights on Bellerophon Therapeutics, Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-0.25.
Whereas they predicted High and Low Earnings Estimate as $-0.25 and $-0.25 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.54.
For the Current Quarter, the growth estimate for Bellerophon Therapeutics, Inc. is 53.7%, while for the Next Quarter the stock growth estimate is 30.8%.
Insider Trades for Bellerophon Therapeutics, Inc. show that the latest trade was made on 15 Mar 2017 where Schoeps (Megan), the Officer completed a transaction type “Buy” in which 24039 shares were traded at a price of $0.
Bellerophon Therapeutics, Inc. (BLPH) has the market capitalization of $51.13 Million. The company rocked its 52-Week High of $4.58 and touched its 52-Week Low of $0.43.
The stock has Return on Assets (ROA) of -86.6 percent. Return on Equity (ROE) stands at -119.1% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 184.62 Percent. The company has Beta Value of 0 and ATR value of 0.13. The Weekly and Monthly Volatility stands at 10.14% and 9.07%.